Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05760638 · ClinicalTrials.gov registry record
Real-World Evidence (RWE) Data Analysis of 1-year Consecutive Use of Remote Electrical Neuromodulation (REN)
A clinical trial, sponsored by Theranica.
- Completed
- Registry status
- 409
- Enrollment target
NCT05760638 is a clinical trial that has completed, run by Theranica. The registered enrollment target is 409 participants.
The verdict
NCT05760638 has completed, sponsored by Theranica.
- COMPLETED
- Registry status
- 409 participants
- Enrollment target
Study Summary
This is a Post-marketing study investigating the long-term safety, utilization, and efficacy of REN during 12 consecutive months of using Nerivio in migraine patients. Safety will be assessed by the number and type of adverse events. Utilization will be measured by the number of monthly treatments. Efficacy will be evaluated as a change in headache pain severity and functional disability from baseline to 2 hours post-treatment in at least 50% of the treatments.
Interventions
- DEVICE Nerivio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 409 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2023-04-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05760638
The ClinicalTrials.gov registry entry for NCT05760638 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 409 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theranica, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nerivio is the first listed.
NCT05760638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05760638 about?
NCT05760638 is a clinical study titled "Real-World Evidence (RWE) Data Analysis of 1-year Consecutive Use of Remote Electrical Neuromodulation (REN)". This is a Post-marketing study investigating the long-term safety, utilization, and efficacy of REN during 12 consecutive months of using Nerivio in migraine patients. Safety will be assessed by the number and type of adverse events. Utilization will be measured by the number of monthly treatments....
What is the current status of trial NCT05760638?
This trial is currently completed. The enrollment target is 409 participants. The study started on 2023-03-01. Estimated completion is 2023-04-02.
What interventions are being tested in trial NCT05760638?
The interventions under investigation include: Nerivio (DEVICE).
Who is sponsoring clinical trial NCT05760638?
This trial is sponsored by Theranica, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.